An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells

International Journal of Cancer

Volumn 124, Issue 3, 2009, Pages 622-629

  Dewan, Md Zahidunnabi ^a,b   Tomita, Mariko ^c   Katano, Harutaka ^b   Yamamoto, Naoki ^a,b,c   Yamamoto, Norio ^a   Ahmed, Sunjida ^a   Yamamoto, Michiko ^d   Sata, Tetsutaro ^b   Mori, Naoki ^b,c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

LCLs; NF B; NOG mice; Ritonavir

Indexed keywords

CYCLIN D2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RITONAVIR; SURVIVIN; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; IN VITRO STUDY; LYMPHOBLASTOID CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; ANIMAL; B CELL LYMPHOMA; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; FLUORESCENCE IN SITU HYBRIDIZATION; GEL MOBILITY SHIFT ASSAY; HUMAN; METABOLISM; POLYMERASE CHAIN REACTION; VIROLOGY; VIRUS INFECTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HIV PROTEASE INHIBITORS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL; MICE; NF-KAPPA B; POLYMERASE CHAIN REACTION; RITONAVIR; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149306379     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23993     Document Type: Article

References (35)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, ed. Fields virology, 4th edn. New York (NY): Lippincott Williams and Wilkins, 2001. Vol. 1,2575-627.
2. Kieff E, Rickinson AB. Epstein-Barr virus and replication. In: Fields BN, ed. Fields virology, 4th ed. New York (NY): Lippincott Williams and Wilkins, 2001. Vol. 1, 2511-73.
3. Zur Hausen H, Schulte-Holthausen H. Presence of EB virus nucleic acid homology in a "virus-free" line of Burkitt tumour cells. Nature 1970;227:245-48.
4. Nonoyama M, Pagano JS. Homology between Epstein-Barr virus DNA and viral DNA from Burkitt's lymphoma and nasopharyngeal carcinoma determined by DNA-DNA reassociation kinetics. Nature 1973;242:44-7.
5. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 1992;66:122-31.
6. Yamamoto N, Takizawa T, Iwanaga Y, Shimizu N, Yamamoto N. Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs. FEBS Lett 2000;484:153-58.
7. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-99.
8. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW, Yamamoto N. Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood 1999;93:2360-8.
9. Baldwin AS. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1999;14:649-81.
10. Guinness ME, Kenney JL, Reiss M, Lacy J. Bcl-2 antisense oligo-deoxynucleotide therapy of Epstein-Barr virus-associated lymphopro-liferative disease in severe combined immunodeficient mice. Cancer Res 2000;60:5354-8.
11. Miyake A, Dewan MZ, Ishida T, Watanabe M, Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T, Horie R. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect 2008;10:748-56.
12. Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, Mizoguchi H, Honda M, Sata T, Watanabe T, Yamamoto N, Ume-zawa K, et al. A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005;114:32-8.
13. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2001;18:109-21.
14. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The protea-some inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
15. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
16. null mice: suppression by an inhibitor against NF-κB. J Virol 2003;77:5286-94.
17. Kitajima I, Shinohara T, Bilakovics J, Brown DA, Xu X, Nerenberg M. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 1992;258:1792-5.
18. Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y, Tomonaga M, Yamamoto N, Fujii M. Bay 11-7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002;100:1828-34.
19. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002;62: 1083-6.
20. Dewan MZ, Uchihara JN, Terashima K, Honda M, Sata T, Ito M, Fujii N, Uozumi K, Tsukasaki K, Tomonaga M, Kubuki Y, Okayama A, et al. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 2006;107:716-24.
21. Cahir-McFarland ED, Davidso DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 2000;97:6055-60.
22. Collier AC. Efficacy of combination antiretroviral therapy. Adv Exp Med Biol 1996;394:355-72.
23. Collier AC, Coombs RW, Schoenfeld DA, Bassett R, Baruch A, Corey L. Combination therapy with zidovudine, didanosine and saqui-navir. Antiviral Res 1996;29:99.
24. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996;334:1011-17.
25. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, Ho DD. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-39.
26. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong XP, Wideburg NE, Saldivar A, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484-88.
27. Andre P, Groettrup M, Klenerman P, de Giuli R, Booth BL, Jr, Cerun-dolo V, Bonneville M, Jotereau F, Zinkernagel RM, Lotteau V. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998; 95:13120-24.
28. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, Sturley SL. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001;7:1327-31.
29. Schmidtke G, Holzhütter HG, Bogyo M, Kairies N, Groll M, de Giuli R, Emch S, Groettrup M. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 1999;274:35734-40.
30. Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freu-denberg M, Galanos C, Niedermann G. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002;62:6901-8.
31. Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz JMS, Weichold FF. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002;99:3771-9.
32. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002;8:225-32.
33. Katano H, Pesnicak H, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004;101:4960-5.
34. Norvir, Ritonavir Product monograph. North Chicago, IL: Abbott laboratories, 1997.
35. Gatti G, Di Biagio A, Casazza R, De Pascalis C, Bassetti M, Cruciani M, Vella S, Bassetti D. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999;13:2083-9.